Replies to post #780972 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

No more labeling phase, LOL? ;)

[AllSheWrote]

For you, it has turned into a whole lot of risk and zero reward.

[10baggerz]

Oh so now we’re resorting to the pathetic “buy more cheapies” line? This is INSANE. The company has diluted 500,000,000 shares since we applied for MAA approval 600 DAYS AGO. They are perfectly content/helpless to continue to dilute no matter how low the price goes…

Yet they can’t be bothered to pay to keep their pathetic website online or do anything to protect the shareholders whose suffering has made this all possible?

I believe we will eventually get MAA approval, which is why I’m still invested despite being down $700,000 since the spike to .47 but it’s getting hard to ignore the fact that something might be terribly wrong. Not hard for you though, because no matter what your AI can put a wildly positive spin on even the most disturbingly negative FACTS.

[jesster64]

Sorry, my frustration might be showing, but

"It’s also important to remember that remaining silent during the MHRA review is standard practice. When you’re in the middle of a first-in-class, process-defined, tissue-agnostic approval, regulators are setting precedent. Any misstep, even an innocently worded update, can cause delays by breaching confidentiality, creating inconsistencies between submissions and public statements, or signaling outcomes prematurely. That’s why companies go quiet until the decision is final."

I thought we were in labeling phase , so the "upsetting the MHRA decision" should be over with.

"This wait hasn’t been idle. In the background, they’ve expanded their patent portfolio, scaled manufacturing capacity, validated their method in academic settings, and aligned their operations with frameworks like SI 87 so approvals can cascade internationally. Every one of those steps has been done with the endgame in mind."

so why no PR about these things? They have nothing to do with the decision if dc-vax is approved or not.

"but price right now is about sentiment, not science or readiness."

right now its about communication.

"tissue-agnostic approval"
where is the evidence? Last I heard, they applied for treatment of 1 cancer.

" We’ve seen ample evidence that they’ve been working hard this entire time: building a regulatory framework, collaborating with top academic centers, securing ironclad IP, and establishing a manufacturing process that’s first in class."

if we have seen ample evidence, why hasn't the investing community seen it or reacted to it?

I have a colonoscopy on thursday. Might as well let the doctor ream me out along with an unamed company ...
I'd be interested in seeing what the dilution has been for the past few days.

[barnstormer]

Slave, thanks for the response. My frustration isn't with the current process. Stopped keeping track of the days about a month ago. I believe the latest estimates were that approval should come sometime in August, but I've become so used to the wait that I've already moved the goal posts into September. My gripe with the company's communications go for back several years prior to the MAA submission. Something they've never been consistently good at in my opinion. I do wonder why they can't comment on some of the things listed in your post. Public knowledge, you (and others) can comment on them, but the company can't?
Thanks